Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.

NCT ID: NCT07188441

Last Updated: 2025-09-23

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-08-13
• Study Completion Date: 2026-12-31

Brief Summary

This trial is a prospective single arm intervention study, conducting clinical research on marketed drugs. Adverse drug reactions are controllable and the risk is low, with an estimated total of 40 cases. The main objective is to evaluate the safety and efficacy of teniposide combined with cisplatin in the treatment of newly diagnosed central malignant germ cell tumors, and to conduct drug monitoring on subjects to explore potential biomarkers for predicting therapeutic efficacy. It is expected to ultimately achieve the goal of prolonging the overall survival of patients, while providing more guidance for the screening of the best treatment population and biological predictive markers.

Detailed Description

The subjects received an injection of teniposide combined with cisplatin every 3 weeks for one cycle. The teniposide dosage was 300 mg/m2, administered continuously over 3 to 5 days, each time with 500 ml of normal saline through intravenous drip; the cisplatin dosage was 75 mg/m2, also administered continuously over 3 to 5 days, for a total of 4-6 cycles. Radiation therapy was conducted according to standard practices after chemotherapy.

Conditions

GCT; Germ Cell Tumor; Central Malignant Germ Cell Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Teniposide plus cisplatin

Our study set up only one experimental group without a control group, and all subjects received the same intervention, namely the combination of Teniposide injection and Cisplatin for the treatment of newly diagnosed central malignant germ cell tumor patients. The effectiveness was assessed by observing the results and comparing them with historical data.

Group Type: EXPERIMENTAL

Teniposide Injection

Intervention Type: DRUG

teniposide 300mg/m2 for 5 days, cisplatin 75mg/m2 for 5 days

Interventions

Teniposide Injection

teniposide 300mg/m2 for 5 days, cisplatin 75mg/m2 for 5 days

Intervention Type: DRUG

Other Intervention Names

cisplatin

Eligibility Criteria

Inclusion Criteria

• Must have at least one measurable lesion defined by RANO criteria
• The initial diagnosis has been confirmed as central malignant germ cell tumor
• Expected survival period ≥ 6 months
• Absolute neutrophil ≥1.0×10^9/L; Platelet ≥100.0×10^9/L
• Aspertate aminotransferase and alanine aminotransferase ≤2.5×Upper limit of normal
• total bilirubin ≤1.5×Upper limit of normal
• Electronic Case Report of Form≥70mL/min/1.73m^2
• Estimated glomerular filtration rate ≥ 70 mL/min/1.73 m² or normal serum creatinine (Cr)
• Women and men with fertility must agree to use appropriate contraceptive methods (hormones or barrier therapy or abstinence) during the study period and within 3 months after the last dose; The pregnancy test of female subjects of childbearing age within 7 days before administration must be negative
• Willing and able to read, understand, and sign written informed consent, parents/guardians of child or adolescent subjects have the ability to understand, agree, and sign research informed consent forms and applicable child consent forms before initiating any protocol related procedures

Exclusion Criteria

• Patients undergoing any other anti-cancer experimental treatment
• Individuals with a history of severe allergies or allergies to any component of the drugs in the past
• Previous or concurrent active cardiovascular diseases with clinical significance, including congenital heart disease or pericardial disease, history of heart failure, myocardial infarction, coronary heart disease, heart valve disease, cardiomyopathy, and arrhythmia
• Patients with Magnetic Resonance Imaging contraindications
• Those who need to receive live virus vaccine during administration
• Serious complications and/or underlying diseases
• Individuals with poor control of hypertension (under standardized blood pressure reduction protocols, systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg)
• Uncontrolled systemic bacterial, viral, or fungal infections
• Patients infected with Human Immunodeficiency Virus(HIV) or syphilis
• Patients who have undergone organ transplantation in the past
• Pregnant or lactating women
• Researchers believe that there are other factors that are not suitable for participating in the experiment

• Minimum Eligible Age: 5 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chengcheng Guo

OTHER

Sponsor Role: lead

Responsible Party

Chengcheng Guo

MD,Principal Investigator,Clinicial Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

chengcheng Guo, Doctor of Medicine

Role: CONTACT

guochch@sysucc.org.cn

020-87343890

Facility Contacts

Chengcheng Guo

Role: primary

guochch@sysucc.org.cn

020-87343890

Other Identifiers

TNBG-002

Identifier Type: -

Identifier Source: org_study_id